EPSTEIN-BARR VIRUS POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for EPSTEIN-BARR VIRUS POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new EPSTEIN-BARR VIRUS POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for EPSTEIN-BARR VIRUS POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug nivolumab takes on EBV-Linked tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…
Matched conditions: EPSTEIN-BARR VIRUS POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo aims to boost CAR T-Cell therapy for rare lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard CAR T-cell therapy can improve outcomes for people with relapsed or refractory primary mediastinal B-cell lymphoma. About 35 participants will receive pembrolizumab before and afte…
Matched conditions: EPSTEIN-BARR VIRUS POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC